Ymeworks Announces New Multispecific Antibody Collaboration With Merck

Ymeworks Announces New Multispecific Antibody Collaboration With Merck

By, Admin 9 July 2020

Zymeworks Inc., A Clinical-Stage Biopharmaceutical Company Developing Multifunctional Biotherapeutics, Announced That It And Longtime Partner, Merck (Known As Msd Outside The Us And Canada) Have Signed A New License Agreement Granting Merck The Right To Develop Additional Multispecific Antibody Therapeutic Candidates Using Zymeworks&Rsquo; Azymetric&Trade; And Efect&Trade; Platforms.Under The Terms Of The New Research And License Agreement, Zymeworks Will Provide Merck A Worldwide, Royalty-Bearing License To Research, Develop And Commercialize Up To Three New Multispecific Antibodies Toward Merck&Rsquo;S Therapeutic Targets. In Exchange, Zymeworks Will Receive An Undisclosed Upfront Payment And If Each Of The Three Programs Yield An Approved Product, Zymeworks Is Eligible To Receive Up To Us$411 Million In Option Exercise Fees And Clinical Development And Regulatory Approval Milestone Payments And Up To Us$480 Million In Commercial Milestone Payments, As Well As Tiered Royalties On Worldwide Sales.Merck Will Also Receive A Worldwide, Royalty-Bearing License To Research, Develop And Commercialize Up To Three Multispecific Antibodies In The Animal Health Field In Exchange For Additional Milestone Payments And Tiered Royalties.&Ldquo;It Is An Exciting Time For The Field Of Bispecific And Multispecific Therapeutics With Candidates Like Zw25 Demonstrating Great Promise In Clinical Trials,&Rdquo; Said Ali Tehrani, Ph.D., President And Ceo Of Zymeworks. &Ldquo;We Are Very Proud That Oncology Leaders Like Merck Recognize The Value Of Our Therapeutic Platforms And Continue To Return For Expanded Access To Our Technology. We Look Forward To Continuing Our Relationship With Merck As They Advance Additional Multispecific Candidates Towards The Clinic.&Rdquo;Zymeworks And Merck Began Working Together In 2011 To Develop Bispecific Antibodies In A Collaboration That Was Expanded In 2014. The New Agreement Does Not Impact The Original Agreement.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!